Financials

Our markets

We are an international pharmaceutical company. Our headquarters are based in Italy, where we are deeply rooted as one of the leading companies in primary care.
Thanks to our 17 subsidiaries around the world and several top distributors, we distribute our products in more than 90 countries, with a global turnover in 2020 of approximately billion euro.
Half of this turnover is a result of our proprietary molecules, designed and developed in our R&D centers (Rifaximin, Sulodexide, Carnitine, L-methylfolate, Parnaparin).
Our second market is the US. After the acquisition of Pamlab in 2016, we now have a strong hold in the nutraceuticals and medical food sectors.
Spain, Romania, France and Poland are our other main markets as well as Russia and China.

Turnover

€ 1,05

billion in 2019

€ 521

million in Italy

€ 534,4

million RoW + Export & Licensing

5 Proprietary
molecules
0%
Other
0%

Turnover

€ 989

millions in 2020

€ 481

millions in Italy

€ 508

millions RoW + Export & Licensing

Others 49% 5 Proprietary molecules (Rifaximin, Sulodexide, Carnitine, L-Methylfolate, Parnaparin) 51%

Headcount

2900

Workforce

1700

Domestic

1200

International

Read More

An international pharmaceutical company founded in Italy, an organization of people led by the passion for pharmaceuticals.
Alfasigma is a leading company in Contract Manufacturing, a unique partner in outsourcing activities for the manufacturing of nearly all pharmaceutical forms.
Stories, updates and media resources about the company and its therapeutic areas, research and sustainability.
×

You’re entering Alfasigma global website

I agree